Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Melanoma | Review

Current understanding of epigenetics role in melanoma treatment and resistance

Authors: Mohsen Karami Fath, Ali Azargoonjahromi, Asma Soofi, Faezeh Almasi, Shahnaz Hosseinzadeh, Saeed Khalili, Kamran Sheikhi, Saeid Ferdousmakan, Soroor Owrangi, Minoovash Fahimi, Hamidreza Zalpoor, Mohsen Nabi Afjadi, Zahra Payandeh, Navid Pourzardosht

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Melanoma is the most aggressive form of skin cancer resulting from genetic mutations in melanocytes. Several factors have been considered to be involved in melanoma progression, including genetic alteration, processes of damaged DNA repair, and changes in mechanisms of cell growth and proliferation. Epigenetics is the other factor with a crucial role in melanoma development. Epigenetic changes have become novel targets for treating patients suffering from melanoma. These changes can alter the expression of microRNAs and their interaction with target genes, which involves cell growth, differentiation, or even death. Given these circumstances, we conducted the present review to discuss the melanoma risk factors and represent the current knowledge about the factors related to its etiopathogenesis. Moreover, various epigenetic pathways, which are involved in melanoma progression, treatment, and chemo-resistance, as well as employed epigenetic factors as a solution to the problems, will be discussed in detail.
Literature
1.
2.
Eggermont AM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.PubMedCrossRef
3.
Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Investig Dermatol. 2021;141(1):23–31.PubMedCrossRef
4.
Payandeh Z, Yarahmadi M, Nariman-Saleh-Fam Z, Tarhriz V, Islami M, Aghdam AM, et al. Immune therapy of melanoma: overview of therapeutic vaccines. J Cell Physiol. 2019;234(9):14612–21.CrossRef
5.
Sabit H, Kaliyadan F, Menezes RG. Malignant melanoma: underlying epigenetic mechanisms. Ind J Dermatol Venereol Leprol. 2020;86(5):475.CrossRef
6.
7.
Wu C-T, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science. 2001;293(5532):1103–5.CrossRef
8.
9.
Kumar S, Gonzalez EA, Rameshwar P, Etchegaray J-P. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers. 2020;12(12):3657.PubMedCentralCrossRef
10.
Karami Fath M, Azargoonjahromi A, Jafari N, Mehdi M, Alavi F, Daraei M, et al. Exosome application in tumorigenesis: diagnosis and treatment of melanoma. Med Oncol. 2022;39(2):1–18.CrossRef
11.
Testa U, Castelli G, Pelosi E. Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells. Medical Sciences. 2017;5(4):28.PubMedCentralCrossRef
12.
Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research. 2007;1773(8):1161–76.CrossRef
13.
Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol. 2004;51(5):803–8.PubMedCrossRef
14.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.PubMedPubMedCentral
15.
Ghasemi-Chaleshtari M, Kiaie SH, Irandoust M, Karami H, Nabi Afjadi M, Ghani S, et al. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses. J Cell Physiol. 2020;235(12):10068–80.PubMedCrossRef
16.
Masjedi A, Ahmadi A, Ghani S, Malakotikhah F, Afjadi MN, Irandoust M, et al. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. Nanomed Nanotechnol Biol Med. 2020;29:102240.CrossRef
17.
Esmaily M, Masjedi A, Hallaj S, Afjadi MN, Malakotikhah F, Ghani S, et al. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine. J Control Release. 2020;326:63–74.PubMedCrossRef
18.
Sullivan R, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2013;32(19):2373–9.PubMedCrossRef
19.
Bardeesy N, Kim M, Xu J, Kim R-S, Shen Q, Bosenberg MW, et al. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol. 2005;25(10):4176–88.PubMedPubMedCentralCrossRef
20.
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Investig Dermatol. 2006;126(1):154–60.PubMedCrossRef
21.
Marionnet C, Duval C, Bernerd F. New insights in photoaging process revealed by in vitro reconstructed skin models. Berlin Heidelberg: Springer; 2015.CrossRef
22.
Zalaudek, I., Argenziano, G., Marghoob, A. A., Pellacani, G., & Peter Soyer, H. Dermoscopy and skin cancer. Dermatol Res Pract 2010;2010:867059.PubMedCrossRef
23.
Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, et al. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015;3(15):210.PubMedPubMedCentral
24.
Pierce CJ, Simmons JL, Broit N, Karunarathne D, Ng MF, Boyle GM. BRN2 expression increases anoikis resistance in melanoma. Oncogenesis. 2020;9(7):1–12.CrossRef
25.
Saha B, Pai GB, Subramanian M, Gupta P, Tyagi M, Patro BS, et al. Resveratrol analogue, trans-4, 4′-dihydroxystilbene (DHS), inhibits melanoma tumor growth and suppresses its metastatic colonization in lungs. Biomed Pharmacother. 2018;107:1104–14.PubMedCrossRef
26.
Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor–negative melanoma cells. Can Res. 2008;68(19):7788–94.CrossRef
27.
Herbert K, Binet R, Lambert J-P, Louphrasitthiphol P, Kalkavan H, Sesma-Sanz L, et al. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. Genes Dev. 2019;33(5–6):310–32.PubMedPubMedCentralCrossRef
28.
Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Can Res. 2009;69(20):7969–77.CrossRef
29.
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816–27.PubMedPubMedCentralCrossRef
30.
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138–42.PubMedPubMedCentralCrossRef
31.
Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5(1):1–15.CrossRef
32.
Malekan M, Ebrahimzadeh MA, Sheida F. The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma. Biomed Pharmacother. 2021;141: 111873.PubMedCrossRef
33.
34.
Karami Fath M, Babakhaniyan K, Zokaei M, Yaghoubian A, Akbari S, Khorsandi M, et al. Anti-cancer peptide-based therapeutic strategies in solid tumors. Cell Mol Biol Lett. 2022;27(1):1–26.CrossRef
35.
Karpisheh V, Afjadi JF, Afjadi MN, Haeri MS, Sough TSA, Asl SH, et al. Inhibition of HIF-1α/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. Int J Biol Macromol. 2021;167:1006–19.PubMedCrossRef
36.
37.
38.
Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 2020;20(1):1–11.CrossRef
39.
Špaková I, Graier W, Rabajdová M, Dubayová K, Nagyová V, Mareková M. Hypoxia factors suppression effect on the energy metabolism of a malignant melanoma cell SK-MEL-30. Eur Rev Med Pharmacol Sci. 2020;24(9):4909–20.PubMed
40.
Mostafavi S, Zalpoor H, Hassan ZM. The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. Cell Mol Biol Lett. 2022;27(1):58.PubMedPubMedCentralCrossRef
41.
Martínez-García MÁ, Riveiro-Falkenbach E, Rodríguez-Peralto JL, Nagore E, Martorell-Calatayud A, Campos-Rodríguez F, et al. A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions. Melanoma Res. 2017;27(6):558–64.PubMedCrossRef
42.
Wan J, Wu W. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways. J Exp Clin Cancer Res. 2016;35(1):1–11.CrossRef
43.
Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H, Noda M. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. Oncogene. 2010;29(18):2638–48.PubMedCrossRef
44.
Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem. 2003;278(16):14013–9.PubMedCrossRef
45.
Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32(8):1713–26.PubMedPubMedCentralCrossRef
46.
Zalpoor H, Akbari A, Nabi-Afjadi M. Ephrin (Eph) receptor and downstream signaling pathways: a promising potential targeted therapy for COVID-19 and associated cancers and diseases. Hum Cell. 2022;35(3):952–4.PubMedPubMedCentralCrossRef
47.
Joshi N, Hajizadeh F, Dezfouli EA, Zekiy AO, Afjadi MN, Mousavi SM, et al. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sci. 2021;275: 119369.PubMedCrossRef
48.
Kang S-H, Yu MO, Park K-J, Chi S-G, Park D-H, Chung Y-G. Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma. Neurosurgery. 2010;67(5):1386–95.PubMedCrossRef
49.
50.
Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21(46):7001–10.PubMedCrossRef
51.
Cao H-H, Liu D-Y, Lai Y-C, Chen Y-Y, Yu L-Z, Shao M, et al. Inhibition of the STAT3 signaling pathway contributes to the anti-melanoma activities of Shikonin. Front Pharmacol. 2020;11:748.PubMedPubMedCentralCrossRef
52.
Mu Z, Guo J, Zhang D, Xu Y, Zhou M, Guo Y, et al. Therapeutic effects of Shikonin on skin diseases: a review. Am J Chin Med. 2021;49(08):1871–95.PubMedCrossRef
53.
54.
Karami Fath M, Karimfar N, Fazlollahpour Naghibi A, Shafa S, Ghasemi Shiran M, Ataei M, et al. Revisiting characteristics of oncogenic extrachromosomal DNA as mobile enhancers on neuroblastoma and glioma cancers. Cancer Cell Int. 2022;22(1):1–14.CrossRef
55.
Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27(1):1–25.CrossRef
56.
Meng H, Pang Y, Liu G, Luo Z, Tan H, Liu X. Podocarpusflavone A inhibits cell growth of skin cutaneous melanoma by suppressing STAT3 signaling. J Dermatol Sci. 2020;100(3):201–8.PubMedCrossRef
57.
Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, et al. Ambra1 regulates autophagy and development of the nervous system. Nature. 2007;447(7148):1121–5.PubMedCrossRef
58.
Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol. 2013;15(4):406–16.PubMedCrossRef
59.
Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, Antonioli M, et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J Cell Biol. 2010;191(1):155–68.PubMedPubMedCentralCrossRef
60.
61.
Zalpoor H, Akbari A, Nayerain Jazi N, Liaghat M, Bakhtiyari M. Possible role of autophagy induced by COVID-19 in cancer progression, chemo-resistance, and tumor recurrence. Infectious Agents and Cancer. 2022;17(1):1–4.CrossRef
62.
Li S, Song Y, Quach C, Guo H, Jang G-B, Maazi H, et al. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019;10(1):1–18.
63.
Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini PF, et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat Cell Biol. 2015;17(1):20–30.PubMedCrossRef
64.
Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592(7856):799–803.PubMedPubMedCentralCrossRef
65.
Ellis R, Tang D, Nasr B, Greenwood A, McConnell A, Anagnostou M, et al. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. Br J Dermatol. 2020;182(1):156–65.PubMed
66.
67.
Rosenkranz A, Slastnikova T, Durymanov M, Sobolev A. Malignant melanoma and melanocortin 1 receptor. Biochem Mosc. 2013;78(11):1228–37.CrossRef
68.
Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38.PubMedCrossRef
69.
González-Ruiz L, González-Moles MÁ, González-Ruiz I, Ruiz-Ávila I, Ayén Á, Ramos-García P. An update on the implications of cyclin D1 in melanomas. Pigment Cell Melanoma Res. 2020;33(6):788–805.PubMedCrossRef
70.
Muñoz-Couselo E, Adelantado EZ, Ortiz C, García JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017;10:3941.PubMedPubMedCentralCrossRef
71.
Ponti G, Manfredini M, Greco S, Pellacani G, Depenni R, Tomasi A, et al. BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival. Anticancer Res. 2017;37(12):7043–8.PubMed
72.
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.PubMedPubMedCentralCrossRef
73.
Xu D, Yuan R, Gu H, Liu T, Tu Y, Yang Z, et al. The effect of ultraviolet radiation on the transforming growth factor beta 1/Smads pathway and p53 in actinic keratosis and normal skin. Arch Dermatol Res. 2013;305(9):777–86.PubMedCrossRef
74.
Hajkova N, Hojny J, Nemejcova K, Dundr P, Ulrych J, Jirsova K, et al. Germline mutation in the TP53 gene in uveal melanoma. Sci Rep. 2018;8(1):1–7.CrossRef
75.
Zhang H, Rosdahl I. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells. Int J Oncol. 2004;24(2):331–5.PubMed
76.
Mologni L, Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, et al. Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells. Neoplasia. 2018;20(5):467–77.PubMedPubMedCentralCrossRef
77.
O’Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. Therapeutic targeting of PP2A. Int J Biochem Cell Biol. 2018;96:182–93.PubMedCrossRef
78.
Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015;47(12):1408–10.PubMedPubMedCentralCrossRef
79.
Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Can Res. 2007;67(6):2632–42.CrossRef
80.
Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol. 2014;71(5):888–95.PubMedPubMedCentralCrossRef
81.
Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 2009;19(8):1462–70.PubMedPubMedCentralCrossRef
82.
Zhang Y, Chen Y, Qu H, Wang Y. Methylation of HIF3A promoter CpG islands contributes to insulin resistance in gestational diabetes mellitus. Mol Genet Genomic Med. 2019;7(4): e00583.PubMedPubMedCentralCrossRef
83.
Chai RC, Zhang KN, Liu YQ, Wu F, Zhao Z, Wang KY, et al. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neurosci Ther. 2019;25(3):314–22.PubMedCrossRef
84.
Chae H, Lee S, Nephew KP, Kim S. Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines. BMC Syst Biol. 2016;10(4):433–43.
85.
Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10(2):103–21.PubMedPubMedCentralCrossRef
86.
Yuan Z, Chen S, Gao C, Dai Q, Zhang C, Sun Q, et al. Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy. Bioorg Chem. 2019;87:200–8.PubMedCrossRef
87.
Gujar H, Weisenberger DJ, Liang G. The roles of human DNA methyltransferases and their isoforms in shaping the epigenome. Genes. 2019;10(2):172.PubMedCentralCrossRef
88.
Shen J, Wang S, Zhang Y-J, Wu H-C, Kibriya MG, Jasmine F, et al. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics. 2013;8(1):34–43.PubMedPubMedCentralCrossRef
89.
Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. JNCI: J National Cancer Institute. 2018;110(6):677–81.CrossRef
90.
Ming Z, Lim SY, Rizos H. Genetic alterations in the ink4a/arf locus: effects on melanoma development and progression. Biomolecules. 2020;10(10):1447.PubMedCentralCrossRef
91.
Hemminki K, Srivastava A, Rachakonda S, Bandapalli O, Nagore E, Hemminki A, et al. Informing patients about their mutation tests: CDKN2A c. 256G> A in melanoma as an example. Hered Cancer Clin Pract. 2020;18(1):1–6.CrossRef
92.
93.
94.
95.
Lagopati N, Belogiannis K, Angelopoulou A, Papaspyropoulos A, Gorgoulis V. Non-canonical functions of the ARF tumor suppressor in development and tumorigenesis. Biomolecules. 2021;11(1):86.PubMedPubMedCentralCrossRef
96.
97.
Seo J, Seong D, Lee SR, Oh D-B, Song J. Post-translational regulation of ARF: perspective in cancer. Biomolecules. 2020;10(8):1143.PubMedCentralCrossRef
98.
Inoue K, Fry EA. Aberrant expression of p14ARF in human cancers: a new biomarker? Tumor Microenviron. 2018;1(2):37.PubMedCrossRef
99.
Ecsedi S, Hernandez-Vargas H, Lima SC, Vizkeleti L, Toth R, Lazar V, et al. DNA methylation characteristics of primary melanomas with distinct biological behaviour. PLoS ONE. 2014;9(5): e96612.PubMedPubMedCentralCrossRef
100.
De Araújo ÉS, Pramio DT, Kashiwabara AY, Pennacchi PC, Maria-Engler SS, Achatz MI, et al. DNA methylation levels of melanoma risk genes are associated with clinical characteristics of melanoma patients. Biomed Res Int. 2015;2015:1.CrossRef
101.
Yang J, Yi N, Zhang J, He W, He D, Wu W, et al. Generation and characterization of a hypothyroidism rat model with truncated thyroid stimulating hormone receptor. Sci Rep. 2018;8(1):1–9.
102.
Koroknai V, Szász I, Hernandez-Vargas H, Fernandez-Jimenez N, Cuenin C, Herceg Z, et al. DNA hypermethylation is associated with invasive phenotype of malignant melanoma. Exp Dermatol. 2020;29(1):39–50.PubMedCrossRef
103.
Jin S, Wu J, Zhu Y, Gu W, Wan F, Xiao W, et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in silico. J Cancer. 2018;9(22):4108.PubMedPubMedCentralCrossRef
104.
Rowland TJ, Bonham AJ, Cech TR. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers. Mol Oncol. 2020;14(10):2358–74.PubMedPubMedCentralCrossRef
105.
Kashyap MP, Sinha R, Mukhtar MS, Athar M. Epigenetic regulation in the pathogenesis of non-melanoma skin cancer. Semin Cancer Biol. 2020;83:36.PubMedCrossRef
106.
Chai P, Jia R, Li Y, Zhou C, Gu X, Yang L, et al. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. Prog Retin Eye Rese. 2021;89:101030.CrossRef
107.
Fröhlich A, Loick S, Bawden EG, Fietz S, Dietrich J, Diekmann E, et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4–1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 2020;52: 102647.PubMedPubMedCentralCrossRef
108.
Sang Y, Deng Y. Current insights into the epigenetic mechanisms of skin cancer. Dermatol Ther. 2019;32(4): e12964.PubMedCrossRef
109.
Hałasa M, Wawruszak A, Przybyszewska A, Jaruga A, Guz M, Kałafut J, et al. H3K18Ac as a marker of cancer progression and potential target of anti-cancer therapy. Cells. 2019;8(5):485.PubMedCentralCrossRef
110.
Chan JC, Maze I. Histone crotonylation makes its mark in depression research. Biol Psychiat. 2019;85(8):616.PubMedCrossRef
111.
112.
Zhang K, Dent SY. Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem. 2005;96(6):1137–48.PubMedCrossRef
113.
Zhang L, Lu Q, Chang C. Epigenetics in health and disease. In: Chang C, Lu Q, editors. Epigenetics in allergy and autoimmunity. Singapore: Springer; 2020.
114.
Xu S, Hui Y, Shu J, Qian J, Li L. Characterization of the human mucin 5AC promoter and its regulation by the histone acetyltransferase P300. Int J Mol Med. 2019;43(3):1263–70.PubMedPubMedCentral
115.
Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem. 2016;121:451–83.PubMedCrossRef
116.
Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, et al. Systematic epigenomic analysis reveals chromatin states associated with melanoma progression. Cell Rep. 2017;19(4):875–89.PubMedPubMedCentralCrossRef
117.
Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 2012;90(1):55–65.PubMedCrossRef
118.
Villagra A, Sotomayor E, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene. 2010;29(2):157–73.PubMedCrossRef
119.
Woan K, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9(7):1447–57.PubMedPubMedCentralCrossRef
120.
McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.PubMedCrossRef
121.
Yeon M, Kim Y, Jung HS, Jeoung D. Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol. 2020;8:486.PubMedPubMedCentralCrossRef
122.
Sefid F, Payandeh Z, Azamirad G, Baradaran B, Nabi Afjadi M, Islami M, et al. Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study. In Silico Pharmacology. 2021;9(1):1–12.CrossRef
123.
Flørenes VA, Skrede M, Jørgensen K, Nesland JM. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res. 2004;14(3):173–81.PubMedCrossRef
124.
Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. 2017;8(47):83155.PubMedPubMedCentralCrossRef
125.
Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8(10):16367.PubMedPubMedCentralCrossRef
126.
Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Can Res. 2019;79(11):2947–61.CrossRef
127.
Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, et al. The role of histone deacetylase inhibitors in uveal melanoma: current evidence. Anticancer Res. 2018;38(7):3817–24.PubMedCrossRef
128.
Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem. 2020;27(15):2449–93.PubMedCrossRef
129.
130.
Powers JJ, Maharaj KK, Sahakian E, Xing L, PerezVillarroel P, Knox T, et al. Histone deacetylase 6 (HDAC6) as a regulator of immune check-point molecules in chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):3311.CrossRef
131.
Lechner S, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022;18:812–820.PubMedCrossRef
132.
Lechner S, Malgapo MIP, Grätz C, Steimbach RR, Baron A, Rüther P, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nature Chem Biol. 2022;18:812.CrossRef
133.
Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4(4):505–24.PubMedCrossRef
134.
Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15(3):249–54.PubMedCrossRef
135.
Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science. 2016;351(6272):aad2197.PubMedPubMedCentralCrossRef
136.
Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, et al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET 151. Pigment Cell Melanoma Res. 2014;27(6):1126–37.PubMedCrossRef
137.
Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Can Res. 2013;73(20):6264–76.CrossRef
138.
Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, et al. Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene. Mol Cell. 2017;68(4):731-44.e9.PubMedPubMedCentralCrossRef
139.
Chory EJ, Calarco JP, Hathaway NA, Bell O, Neel DS, Crabtree GR. Nucleosome turnover regulates histone methylation patterns over the genome. Mol Cell. 2019;73(1):61-72.e3.PubMedCrossRef
140.
Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther. 2017;17(6):709–21.PubMedCrossRef
141.
142.
Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y, et al. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int J Cancer. 2019;145(12):3462–77.PubMedCrossRef
143.
Orouji E, Utikal J. Tackling malignant melanoma epigenetically: histone lysine methylation. Clin Epigenetics. 2018;10(1):1–16.CrossRef
144.
Kuźbicki Ł, Lange D, Stanek-Widera A, Chwirot BW. Prognostic significance of RBP2-H1 variant of JARID1B in melanoma. BMC Cancer. 2017;17(1):1–7.CrossRef
145.
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma. Nature. 2011;471(7339):513.PubMedPubMedCentralCrossRef
146.
Watanabe H, Soejima K, Yasuda H, Kawada I, Nakachi I, Yoda S, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int. 2008;8(1):1–12.CrossRef
147.
Sengupta D, Byrum SD, Avaritt NL, Davis L, Shields B, Mahmoud F, et al. Quantitative histone mass spectrometry identifies elevated histone H3 lysine 27 (Lys27) trimethylation in melanoma. Mol Cell Proteomics. 2016;15(3):765–75.PubMedCrossRef
148.
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res Fundam Mol Mech Mutagen. 2008;647(1–2):21–9.CrossRef
149.
150.
De Donatis G, Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, et al. NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. Oncogene. 2016;35(21):2735–45.PubMedCrossRef
151.
Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, et al. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget. 2015;6(29):27023.PubMedPubMedCentralCrossRef
152.
Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583–94.PubMedPubMedCentralCrossRef
153.
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957–9.PubMedPubMedCentralCrossRef
154.
155.
Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40(5):841–9.PubMedPubMedCentralCrossRef
156.
Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE. 2010;5(11): e13779.PubMedPubMedCentralCrossRef
157.
Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. PLoS ONE. 2013;8(9): e73473.PubMedPubMedCentralCrossRef
158.
Bell RE, Khaled M, Netanely D, Schubert S, Golan T, Buxbaum A, et al. Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Investig Dermatol. 2014;134(2):441–51.PubMedCrossRef
159.
Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer. 2011;129(5):1064–74.PubMedCrossRef
160.
Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Can Res. 2012;72(18):4629–41.CrossRef
161.
Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, Laterra J. Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G1 is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol. 2002;22(8):2703–15.PubMedPubMedCentralCrossRef
162.
Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18(5):549–57.PubMedCrossRef
163.
Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JG, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010;176(5):2520–9.PubMedPubMedCentralCrossRef
164.
Felicetti F, Errico MC, Segnalini P, Mattia G, Carè A. MicroRNA-221 and-222 pathway controls melanoma progression. Expert Rev Anticancer Ther. 2008;8(11):1759–65.PubMedCrossRef
165.
166.
167.
Liu C, Lu J, Tian H, Du W, Zhao L, Feng J, et al. Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep. 2017;15(3):1063–70.PubMedPubMedCentralCrossRef
168.
Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S, et al. miR-146a controls immune response in the melanoma microenvironment. Can Res. 2019;79(1):183–95.CrossRef
169.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance. 2019;2(2):141–60.PubMedPubMedCentral
170.
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339.PubMedPubMedCentralCrossRef
171.
Seghers AC, Wilgenhof S, Lebbé C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012;22(6):466–72.PubMedCrossRef
172.
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69–80.PubMedPubMedCentralCrossRef
173.
Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell. 2013;23(6):811–25.PubMedCrossRef
174.
Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2015;34(34):4448–59.CrossRef
175.
Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016;18(10):1090–101.PubMedPubMedCentralCrossRef
176.
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–7.PubMedCrossRef
177.
Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, et al. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget. 2014;5(8):2085.PubMedPubMedCentralCrossRef
178.
Bajpe P, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2015;34(4):531–6.PubMedCrossRef
179.
Strub T, Ghiraldini FG, Carcamo S, Li M, Wroblewska A, Singh R, et al. SIRT6 haploinsufficiency induces BRAF V600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun. 2018;9(1):1–13.CrossRef
180.
Sundaresan NR, Vasudevan P, Zhong L, Kim G, Samant S, Parekh V, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 2012;18(11):1643–50.PubMedPubMedCentralCrossRef
181.
Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res. 2011;17(4):721–30.PubMedCrossRef
182.
Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF–targeted melanoma cells. Can Res. 2010;70(16):6670–81.CrossRef
183.
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, et al. Recurrent tumor cell–intrinsic and–extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 2017;7(11):1248–65.PubMedPubMedCentralCrossRef
184.
Guo W, Ma J, Yang Y, Guo S, Zhang W, Zhao T, et al. ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition. Clin Cancer Res. 2020;26(11):2725–39.PubMedCrossRef
185.
Avril MF, Aamdal S, Grob J, Hauschild A, Mohr P, Bonerandi J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118–25.PubMedCrossRef
186.
Christmann M, Verbeek B, Roos WP, Kaina B. O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2011;1816(2):179–90.CrossRef
187.
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.PubMedCrossRef
188.
Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer. 2001;92(1):123–9.PubMedCrossRef
189.
Hassel J, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer. 2010;103(6):820–6.PubMedPubMedCentralCrossRef
190.
Naumann S, Roos W, Jöst E, Belohlavek C, Lennerz V, Schmidt C, et al. Temozolomide-and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer. 2009;100(2):322–33.PubMedPubMedCentralCrossRef
191.
Thakur MD, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251–5.PubMedPubMedCentralCrossRef
192.
Wang Z, Wu R, Nie Q, Bouchonville KJ, Diasio RB, Offer SM. Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance. J National Cancer Center. 2021;1(1):15–22.CrossRef
193.
Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 2008;22(9):1115–40.PubMedPubMedCentralCrossRef
194.
Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen C-H, et al. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci. 2013;110(45):18226–31.PubMedPubMedCentralCrossRef
195.
Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23(3):302–15.PubMedPubMedCentralCrossRef
196.
Huang P-H, Chen C-H, Chou C-C, Sargeant AM, Kulp SK, Teng C-M, et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol. 2011;79(1):197–206.PubMedPubMedCentralCrossRef
197.
198.
199.
200.
Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med. 2018;378(14):1323–34.PubMedCrossRef
201.
Al Emran A, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40(4):328–44.CrossRef
202.
Zhou L, Xu N, Shibata H, Saloura V, Uppaluri R. Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer Metastasis Rev. 2021;40(1):141–52.PubMedPubMedCentralCrossRef
203.
Jung H, Kim HS, Kim JY, Sun J-M, Ahn JS, Ahn M-J, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278.PubMedPubMedCentralCrossRef
204.
You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C, et al. Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells. Front Immunol. 2020;11:1787.PubMedPubMedCentralCrossRef
205.
Grunewald CM, Schulz WA, Skowron MA, Hoffmann MJ, Niegisch G. Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance. Transl Cancer Rese. 2018;7(4):1151–60.CrossRef
206.
Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D, et al. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016;7(33):53735.PubMedPubMedCentralCrossRef
207.
Bell RE, Levy C. The three M’s: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res. 2011;24(6):1088–106.PubMedCrossRef
208.
Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;20(24):3426–39.PubMedPubMedCentralCrossRef
209.
210.
Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Can Res. 2011;71(11):3852–62.CrossRef
211.
Siena ÁDD, Plaça JR, Araújo LF, de Barros II, Peronni K, Molfetta G, et al. Whole transcriptome analysis reveals correlation of long noncoding RNA ZEB1-AS1 with invasive profile in melanoma. Sci Rep. 2019;9(1):1–11.CrossRef
212.
Chen L, Yang H, Xiao Y, Tang X, Li Y, Han Q, et al. Lentiviral-mediated overexpression of long non-coding RNA GAS5 reduces invasion by mediating MMP2 expression and activity in human melanoma cells. Int J Oncol. 2016;48(4):1509–18.PubMedCrossRef
213.
Wu L, Zhu L, Li Y, Zheng Z, Lin X, Yang C. LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis. Cancer Cell Int. 2020;20(1):1–14.CrossRef
214.
Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, et al. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget. 2015;6(19):17753.PubMedPubMedCentralCrossRef
215.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7(4):4428.PubMedCrossRef
216.
Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, et al. Micro RNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res. 2017;30(3):328–38.PubMedPubMedCentralCrossRef
217.
Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixidó J. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma. Can Res. 2018;78(4):1017–30.CrossRef
218.
219.
Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 2016;7(37):59209.PubMedPubMedCentralCrossRef
220.
Venza M, Visalli M, Catalano T, Beninati C, Teti D, Venza I. DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients. Hum Pathol. 2017;60:137–46.PubMedCrossRef
221.
van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, et al. Promoter hypermethylation: a common cause of reduced p16INK4a expression in uveal melanoma. Can Res. 2001;61(13):5303–6.
222.
Pfeifer GP, et al. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383(6):907–14.PubMedCrossRef
223.
Olvedy M, Tisserand JC, Luciani F, Boeckx B, Wouters J, Lopez S, et al. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. J Clin Investig. 2017;127(6):2310–25.PubMedPubMedCentralCrossRef
224.
Nogueira C, Kim K-H, Sung H, Paraiso K, Dannenberg J-H, Bosenberg M, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010;29(47):6222–32.PubMedPubMedCentralCrossRef
225.
Martinez-Cardús A, Vizoso M, Moran S, Manzano JL. Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance. Ann Transl Med. 2015;3(15):209.PubMedPubMedCentral
226.
Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017;9(1):1–15.CrossRef
227.
Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, et al. Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation. J Investig Dermatol. 2015;135(7):1820–8.PubMedCrossRef
228.
Rodger EJ, Chatterjee A, Stockwell PA, Eccles MR. Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types. Clin Epigenetics. 2019;11(1):1–11.CrossRef
229.
Wischnewski F, Friese O, Pantel K, Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res. 2007;5(7):749–59.PubMedCrossRef
230.
Echevarría-Vargas, I. M., Reyes-Uribe, P. I., Guterres, A. N., Yin, X., Kossenkov, A. V., Liu, Q., et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018;10(5):e8446.PubMedPubMedCentralCrossRef
231.
Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D’Alesio C, et al. In vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype. Cancer Discov. 2016;6(6):650–63.PubMedCrossRef
232.
Uzdensky A, Demyanenko S, Bibov M, Sharifulina S, Kit O, Przhedetski Y, et al. Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin. Tumor Biology. 2014;35(8):8225–33.PubMedCrossRef
233.
Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, et al. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Investig Dermatol. 2013;133(10):2444–52.PubMedCrossRef
234.
Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res. 2005;304(1):244–55.PubMedCrossRef
235.
Li L, Zhang Z, Ma T, Huo R. PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM. Mol Med Rep. 2016;14(1):521–8.PubMedCrossRef
236.
Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016;10(5):735–50.PubMedCentralCrossRef
237.
Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Can Res. 2005;65(6):2260–8.CrossRef
238.
Liu DZ, Cheng Y, Cai RQ, Wang Bd WW, Cui H, Liu M, et al. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. Nanomedicine. 2018;14(3):991–1003.PubMedCrossRef
239.
Schmitz SU, Albert M, Malatesta M, Morey L, Johansen JV, Bak M, et al. Jarid1b targets genes regulating development and is involved in neural differentiation. EMBO J. 2011;30(22):4586–600.PubMedPubMedCentralCrossRef
240.
Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, et al. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol. 2015;28(7):884–94.PubMedCrossRef
241.
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–63.PubMedPubMedCentralCrossRef
242.
Wang J, Chen J, Jing G, Dong D. LncRNA HOTAIR promotes proliferation of malignant mela-noma cells through NF-κB pathway. Iran J Public Health. 2020;49(10):1931–9.PubMedPubMedCentral
243.
Cai B, Zheng Y, Ma S, Xing Q, Wang X, Yang B, et al. BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR-204. Int J Oncol. 2017;51(6):1941–51.PubMedCrossRef
244.
Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531(7595):518–22.PubMedCrossRef
245.
Tian Y, Zhang X, Hao Y, Fang Z, He Y. Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma. Melanoma Res. 2014;24(4):335–41.PubMedCrossRef
246.
Wu C-F, Tan G-H, Ma C-C, Li L. The non-coding RNA llme23 drives the malignant property of human melanoma cells. J Genet Genomics. 2013;40(4):179–88.PubMedCrossRef
247.
Laurette P, Coassolo S, Davidson G, Michel I, Gambi G, Yao W, et al. Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma. Cell Death Differ. 2020;27(1):29–43.PubMedCrossRef
248.
Qadeer ZA, Harcharik S, Valle-Garcia D, Chen C, Birge MB, Vardabasso C, et al. Decreased expression of the chromatin remodeler ATRX associates with melanoma progression. J Invest Dermatol. 2014;134(6):1768.PubMedPubMedCentralCrossRef
249.
Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, et al. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy. J National Cancer Institute. 2015;107(5):djv034.CrossRef
250.
Huang JM, Hornyak TJ. Polycomb group proteins–epigenetic repressors with emerging roles in melanocytes and melanoma. Pigment Cell Melanoma Res. 2015;28(3):330–9.PubMedPubMedCentralCrossRef
251.
Mascolo M, Vecchione ML, Ilardi G, Scalvenzi M, Molea G, Di Benedetto M, et al. Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer. 2010;10(1):1–14.CrossRef
252.
Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature. 2010;468(7327):1105–9.PubMedPubMedCentralCrossRef
253.
Duarte LF, Young AR, Wang Z, Wu H-A, Panda T, Kou Y, et al. Histone H3 3 and its proteolytically processed form drive a cellular senescence programme. Nature Commun. 2014;5(1):1–12.CrossRef
254.
Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, et al. Histone variant H2A. Z. 2 mediates proliferation and drug sensitivity of malignant melanoma. Mol Cell. 2015;59(1):75–88.PubMedPubMedCentralCrossRef
255.
Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009;15(7):2479–87.PubMedCrossRef
256.
Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer. 2009;100(1):28–36.PubMedPubMedCentralCrossRef
257.
Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, et al. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metas. 2008;25(7):703–16.CrossRef
258.
Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002;8(7):2142–8.PubMed
259.
Pontiki E, Hadjipavlou-Litina D. Histone deacetylase inhibitors (HDACIs). Structure—Activity relationships: History and new QSAR perspectives. Med Res Rev. 2012;32(1):1–165.PubMedCrossRef
260.
Gore L, Rothenberg ML, O’Bryant CL, Schultz MK, Sandler AB, Coffin D, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14(14):4517–25.PubMedPubMedCentralCrossRef
Metadata
Title
Current understanding of epigenetics role in melanoma treatment and resistance
Authors
Mohsen Karami Fath
Ali Azargoonjahromi
Asma Soofi
Faezeh Almasi
Shahnaz Hosseinzadeh
Saeed Khalili
Kamran Sheikhi
Saeid Ferdousmakan
Soroor Owrangi
Minoovash Fahimi
Hamidreza Zalpoor
Mohsen Nabi Afjadi
Zahra Payandeh
Navid Pourzardosht
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02738-0

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Primary research

Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers

Hypothesis

Prostate cancer in omics era

Primary research

Prognostic value and biological function of LRRN4 in colorectal cancer

Review

Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment

Research

Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line derived from a Chinese patient

Review

Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits